Материал и методы

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2020-31-36

rsp-2840

Research Article

ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ

ORIGINAL RESEARCH

Переносимость инфликсимаба у пациентов с ревматоидным артритом в реальной клинической практике

Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice

Аронова

Е. С.

Aronova

E. S.

Евгения Сергеевна Аронова

15522, Москва, Каширское шоссе, 34А

Evgenia Aronova

34A, Kashirskoe Shosse, Moscow 115522

eugpozd@mail.ru

Лукина

Г. В.

Lukina

G. V.

15522, Москва, Каширское шоссе, 34А; 111123, Москва, шоссе Энтузиастов, 86

34A, Kashirskoe Shosse, Moscow 115522; 86, Enthusiasts Shosse, Moscow 111123

Сигидин

Я. А.

Sigidin

Ya. A.

15522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ Научноисследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой; ГБУЗ г. Москвы «Московский клинический научнопрактический центр им. А.С. Логинова» Департамента здравоохранения г. МосквыРоссияV.A. Nasonova Research Institute of Rheumatology; A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare DepartmentRussian Federation

2020

19022020

5813136

2020

Аронова Е.С., Лукина Г.В., Сигидин Я.А.

Aronova E.S., Lukina G.V., Sigidin Y.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2840

Широкий спектр генно-инженерных биологических препаратов, введенных в клиническую ревматологию за последние годы, обусловливает особый интерес к их переносимости. В статье представлены собственные данные авторов, а также обзор зарубежной литературы, посвященной данному вопросу.

Цель исследования — проанализировать переносимость инфликсимаба (ИНФ) у больных ревматоидным артритом (РА) в реальной клинической практике.

Материал и методы

Материал и методы. В анализ было включено 135 больных РА, получавших ИНФ в комбинации с базисными противовоспалительными препаратами или в виде монотерапии.

Результаты и обсуждение

Результаты и обсуждение. Общая переносимость ИНФ была удовлетворительной. Неблагоприятные реакции (НР) отмечались в 28,1% случаев, в том числе у 19 (14,1%) пациентов — серьезные НР, потребовавшие отмены препарата.

Заключение

Заключение. Наилучшая переносимость отмечалась при использовании комбинации ИНФ и метотрексата. Авторы обращают внимание на необходимость врачебного осмотра перед каждым введением препарата.

A wide range of biological agents recently introduced into clinical rheumatology determines a special interest in their tolerance. The paper presents the authors’ own data, as well as a review of foreign literature on this issue.

Objective

Objective: to analyze the tolerability of infliximab (INF) in patients with rheumatoid arthritis (RA) in real clinical practice

Subjects and methods

Subjects and methods. The analysis included 135 RA patients receiving INF alone or in combination with diseasemodifying antirheumatic drugs.

Results and discussion

Results and discussion. The total tolerance of INF was satisfactory. Adverse reactions (ARs) were noted in 28.1% of cases, including in 19 (14.1%) patients who had serious ARs that required drug discontinuation.

Conclusion

Conclusion. The best tolerance was observed with a combination of INF and methotrexate. The authors draw attention to the need for medical examination prior to each drug administration.

биологическая терапиягенно-инженерные биологические препаратыинфликсимабингибиторы фактора некроза опухоли анеблагоприятные реакцииревматоидный артрит

biological therapybiological agentsinfliximabtumor necrosis factor-а inhibitorsadverse reactionsrheumatoid arthritis

Настоящее исследование выполнено в рамках НИР по теме «Коморбидные инфекции при ревматических заболеваниях и проблемы безопасности антиревматической терапии» (АААА-А19-П902П90148-3, 0514-2019-0005)

References1

Сигидин ЯА, Лукина ГВ. Биологическая терапия в ревматологии. 2-е изд., доп. Москва: Практическая медицина; 2009. 64 с.

Sigidin YaA, Lukina GV. Biologicheskaya terapiya v revma-tologii [Biological therapy in rheumatology]. 2nd ed. Moscow: Prakticheskaya meditsina; 2009. 64 p. (In Russ.).

Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. JRheumatol. 2010;37(5):928-31. doi: 10.3899/jrheum.091107

Galloway JB, Hyrich KL, Mercer LK, et al; BSRBR Control Centre Consortium; on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124-31. doi: 10.1093/rheumatology/keq242

Leombruno J. The challenges of quantifying the risk of serious infection with tumor necrosis factor antagonist therapy. J Rheumatol. 2010 May;37(5):887-9. doi: 10.3899/jrheum.100251

Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692

Hongxing Liao, Zhixiong Zhong, Zhanliang Liu, Xuenong Zou. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20:161-8. doi: 10.1111/1756-185X.12970

Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010 Jul;37(7):1542; author reply 1543. doi: 10.3899/jrheum.100058

Girlanda S, Mantegani P, Baldissera E, et al. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol. 2010 Oct;29(10):1135-41. doi: 10.1007/s10067-010-1532-1. Epub 2010 Jul 20.

Reenaers C, Belaiche J, Louis E. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010 Aug;16(8):1271-2. doi: 10.1002/ibd.21162

Malaviya AN, Kapoor S, Garg S, Rawat R. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India — followup report. J Rheumatol. 2010 Jan;37(1):209. doi: 10.3899/jrheum.090854

Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res Ther. 2010;12:103. doi: 10.1186/ar2899

Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov;90(6):359-71. doi: 10.1097/MD.0b013e3182380a76

Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28;21(36):10274-89. doi: 10.3748/wjg.v21.i36.10274

Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021-9. doi: 10.1007/s10067-010-1523-2

Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130

Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-a inhibitors and chronic hepatitis C: A comprehensive literature review. Clin Gastroenterol Hepatol. 2013 May;11(5):558-64.

Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9.

Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum. 2010;62(11):3191-5. doi: 10.1002/art.27687

Summut L, Wallis D, Holroyd C. Progressive multifocal leukoen-cephalopathy associated with infliximab. JR Coll Physicians (Edinb). 2016 Sep;46(3):163-5. doi: 10.4997/JRCPE.2016.305

Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010 Aug;62(8):2517-24. doi: 10.1002/art.27511

Onel KB, Onel K. Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res (Hoboken). 2010 Apr 21;62(7):1024-8. doi: 10.1002/acr.20228

Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010 Feb;69(2):400-8. doi: 10.1136/ard.2009.117762. Epub 2009 Oct 14.

Chen Y, Friedman M, Liu G, et al. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78-88. doi: 10.1016/j.cyto.2016.09.013

Raaschou P, Simard JF, Hagelberg CA, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016 Jan 28;352:i262. doi: 10.1136/bmj.i262

Amari W, Zeringue AL, McDonald JR, et al. Risk of nonmelanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1431-9. doi: 10.1093/rheumatology/ker113

Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622

Farshid G, Prowse P, True B. Epithelioid myxofibrosarcoma developing at the injection site of Adalimumab therapy for psoriatic synovitis. Eur J Rheumatol. 2018 Jul;5(2):131-4. doi: 10.5152/eur-jrheum.2017.17083

Dixon WG, Watson KD, Lunt M, et al; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129

Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010 Jan 8;12(1):R5. doi: 10.1186/ar2904

Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003

Santos RC, Figuiredo VN, Martins LC, et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras. 2012;58(6):698-702. doi: 10.1590/S0104-42302012000600015

Miehsler W, Novacek G, Wenzl H, et al. Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4: 22156. doi: 10.1016/j.crohns.2009.12.001

Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010 Jun;62(6):764-9. doi: 10.1002/acr.20037

Cancelliere N, Barranco P, Vidaurrazaga C, et al. Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept. JInvestig Alergol Clin Immunol. 2011;21:248-9.

Tugnet N, Youssef A, Whallett AJ. Wells’ syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford). 2012;51:195-6. doi: 10.1093/rheumatology/ker322

Poliak N, Orange JS, Pawel BR, Weiss PF. Eosinophilic fasciitis mimicking angioedema and treatment response to infliximab in a pediatric patient. Ann Allergy Asthma Immunol. 2011;106:444-5. doi: 10.1016/j.anai.2011.01.021

Alshekaili J, Li C, Cook MC. Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment. Rheumatology (Oxford). 2010 May;49(5):891-7. doi: 10.1093/rheumatology/keq018. Epub 2010 Feb 23.

Saraceno R, Specchio F, Torres T, et al. The significance of the development of antinuclear antibodies during infliximab treatment. J Am Acad Dermatol. 2013 Aug;69(2):314. doi: 10.1016/j.jaad.2013.03.020

Vaz JLP, Andrade CAF, Pereira AC, et al. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol. 2013;53(4):358-64. doi: 10.1016/S2255-5021(13)70049-X

Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011 May;50(5):619-25. doi: 10.1111/j.1365-4632.2011.04871.x

Sokolove J, Strand V, Greenberg JD, et al; on behalf of the CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep;69(9):1612-7. doi: 10.1136/ard.2009.112136

Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013 May;11(5):558-64.e3. doi: 10.1016/j.cgh.2012.12.025

Goujon C, Dahel K, Berard F, et al. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol. 2010 Aug;63(2):e43-4. doi: 10.1016/j.jaad.2009.02.029

Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with crohn’s disease with no relapse after switching to adalimumab. BioDrugs. 2010 Dec 14;24 Suppl 1:25-7. doi: 10.2165/11586210-000000000-00000

Kinnunen U, Farkkila M, Makisalo H. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohn’s Colitis. 2012 Jul;6(6):724-7. doi: 10.1016/j.crohns.2012.02.004

Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463. doi: 10.1155/2014/956463

Aasly JO. Bilateral Optic Neuritis Associated with the Use of Infliximab. Case Rep Ophthalmol Med. 2011;2011:232986. doi: 10.1155/2011/232986

Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013 Apr;33(4):1101-3. doi: 10.1007/s00296-011-2316-x

Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new «class effect» paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010 Feb;39(4):313-9. doi: 10.1016/j.semarthrit.2008.11.003

Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010 Jul;146(7):780-4. doi: 10.1001/archdermatol.2010.142

Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther. 2018;43(1):107-9. doi: 10.1111/jcpt.12586

Patwala K, Crump N, De Cruz P. Guillain-Barre syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity. Case Rep. 2017;2017:bcr-2017-219481. doi: 10.1136/bcr-2017-219481

Singh JA, Wells GA, Christensen R, et al Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):Art. No. CD008794. doi: 10.1002/14651858.CD008794

Singh JA, Wells GA, Christensen R, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;(5). doi: 10.1002/14651858.CD012183

Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20. doi: 10.1136/annrheumdis-2012-203090

Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:article number 82. doi: 10.1186/s13075-016-0981-6

Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355-63. doi: 10.1136/annrheumdis-2015-208786

Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091

Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. doi: 10.1186/s13075-016-0930-4

Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346-54. doi: 10.1136/annrheumdis-2015-208783

Каратеев ДЕ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная эффективность и безопасность биоаналога инфликсимаба (BCD-055) и оригинального инфликсимаба у пациентов с ан-килозирующим спондилитом (результаты международных многоцентровых рандомизированных двойных слепых клинических исследований I и III фазы). Современная ревматология. 2017;11(3):14-25

Karateev DE, Mazurov VI, Zonova EV, et al. Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(3):14-25 (In Russ.). doi: 10/14412/1996-7012-2017-3-14-25

Лила АМ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная оценка долгосрочной эффективности и безопасности биоаналога инфликсимаба BCD-055 и референтного инфликсимаба у пациентов с анкилозирующим спондилитом: результаты международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы ASART-2. Научно-практическая ревматология. 2018;56(3):293-301 doi: 10.14412/1995-4484-2018-293-301

Lila AM, Mazurov VI, Zonova EV, et al. Comparative evaluation of the longterm efficacy and safety of the infliximab biosimilar BCD-055 and reference infliximab in patients with ankylosing spondylitis: results of the international multicenter randomized double-blind Phase III clinical study ASART-2. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):293-301 (In Russ.). doi: 10.14412/1995-4484-2018-293-301

The authors declare that there are no conflicts of interest present.